Pay in 4 interest-free payments of $13.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors
is a bioluminescence agent
InChi: InChI=1S/C17H16N8/c1-2-10(1)13-8-16(25-24-13)22-15-5-6-18-17(23-15)21-11-3-4-12-14(7-11)20-9-19-12/h3-10H
Smiles: CC1=NOC2[C@H](CC(N)=O)N=C(C3=CC=CC=C3C=21)C1C=CC(Cl)=CC=1
AZ20 potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses
BX-471 - CAS# 217645-70-0 60310 Exploiting an allosteric binding siteBX 471, CAS No. 217645 70 0, also known as ZK 811752, is a potent, selective non peptide CCR1 antagonist (Ki = 1 nM for human CCR1). BX 471 exhibits 250 fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX 471 was developed Berlex and its parent company, Schering AG. BX 471 is the lead in a series of non peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In
US$ 19.49
US$ 68.00
US$ 400.00
US$ 25.99